Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Weill Cornell Medical College, New York, New York, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Department of Oncology, Ruijin Hospital, Shanghai, China
Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E., Porto, Portugal
AOU Policlinico Dipartimento di Pediatria, Bari, Italy
Ospedale Papa Giovanni XXIII - USS Oncoematologia Pediatrica, Bergamo, Italy
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
Guangzhou 8th People's Hospital, Guangzhou, Guangdong, China
Hematological department, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai, Shanghai, China
U.O.C. Oncoematologia - Istituto Oncologico Veneto Irccs, Presidio Ospedaliero S. Giacomo Apostolo, Castelfranco Veneto, Italy
Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico UOC Oncoematologia, Milano, Italy
Azienda Ospedaliera "S.Gerardo", Monza, Italy
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.